Skip to main content

Advertisement

SpringerLink
Log in

Urinary tract infection following intradetrusor onabotulinumtoxina injection for non-neurogenic urgency incontinence: single- vs. multi-dose prophylactic antibiotic treatment regimens

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

Urinary tract infection is one of the most common adverse events following onabotulinumtoxinA injection for urgency incontinence. Our hypothesis was that those undergoing injection for urgency incontinence who received more than one dose of prophylactic antibiotics have lower post-procedure urinary tract infection rates compared to those who receive a single dose.

Methods

We conducted a multi-center retrospective cohort study in females who underwent onabotulinumtoxinA injection for non-neurogenic urgency incontinence to evaluate the effect of single- vs. multi-dose prophylactic antibiotic regimens on the risk of post-procedure urinary tract infection. The primary outcome was the rate of urinary tract infection within 30 days of injection. Our sample size calculation required 136 subjects per group.

Results

Two hundred eighty-one patients were included from four centers. The single-dose cohort included 145 patients (51.6%), and the multi-dose cohort included 136 patients (48.4%). The mean age was 65 years, and patients were primarily Caucasian (81.4%). There was no difference in the rate of urinary tract infections diagnosed within 30 days of injection between the cohorts (single dose 13.8% vs. multi-dose 10.3%, p = 0.369). Those with a positive urine culture within 30 days of injection had a 15.2 times greater odds of having a post-procedure infection than those who did not (95% CI 3.19–72.53). There was no significant difference between the two cohorts in terms of adverse health events following injection.

Conclusions

In females with non-neurogenic urgency incontinence undergoing onabotulinumtoxinA injection, multi-dose prophylactic antibiotic regimens were not associated with lower post-procedure urinary tract infection rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.

Similar content being viewed by others

References

  1. Gormley E, Lightner D, Burgio K. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline.; 2019. http://www.auanet.org/common/pdf/education/clinical-guidance/Overactive-Bladder.pdf.

  2. Apostolidis A, Dasgupta P, Denys P. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European consensus report. Eur Urol. 2009;55(1):100–20. https://doi.org/10.1016/j.eururo.2008.09.009.

    Article  PubMed  Google Scholar 

  3. Brubaker L, Richter HE, Visco A. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217–22. https://doi.org/10.1016/j.juro.2008.03.028.Refractory.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Visco AG, Brubaker L, Richter HE. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med. 2012;36(19):1803–13. https://doi.org/10.1097/01.ogx.0000427620.34769.ed.

    Article  Google Scholar 

  5. Sievert KD, Chapple C, Herschorn S. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Int J Clin Pract. 2014;68(10):1246–56. https://doi.org/10.1111/ijcp.12443.

    Article  CAS  PubMed  Google Scholar 

  6. Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. Am Urol Assoc Educ Res. 2019;1-65. https://doi.org/10.1097/JU.0000000000000509.

  7. Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. J Urol. 2020;203(6):351–6. https://doi.org/10.1097/JU.0000000000000789.

    Article  PubMed  Google Scholar 

  8. Allergan. Highlights of Prescribing Information. Allergan Pharmaceuticals. https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-prescribing/20190620-BOTOX-100-and-200-Units-v3-0USPI1145-v2-0MG1145.pdf. Published 2021.

  9. Amundsen CL, Richter HE, Menefee SA, et al. Onabotulinumtoxin a vs sacral neuromodulation on refractory urgency urinary incontinence in women: A randomized clinical trial. JAMA - J Am Med Assoc. 2016;316(13):1366–74. https://doi.org/10.1001/jama.2016.14617.

    Article  CAS  Google Scholar 

  10. Houman J, Moradzadeh A, Patel D. What is the ideal antibiotic prophylaxis for intravesical botox injection? A comparison of two different regimens. Int Urogynecol J. 2019;30:701–4 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emex&NEWS=N&AN=616357445.

    Article  PubMed  Google Scholar 

  11. Eckhardt SE, Takashima Y, Handler SJ, Tenggardjaja C, Yazdany T. Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder. Int Urogynecol J. 2021. https://doi.org/10.1007/s00192-021-04691-4.

  12. Bickhaus JA, Vaughan M, Truong T, Li YJ, Siddiqui NY. A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin A injection. Int Urogynecol J. 2020;31(9):1907–12. https://doi.org/10.1007/s00192-020-04230-7.

    Article  PubMed  PubMed Central  Google Scholar 

  13. FDA. FDA In Brief: FDA warns that fluoroquinolone antibiotics can cause aortic aneurysm in certain patients | FDA. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-warns-fluoroquinolone-antibiotics-can-cause-aortic-aneurysm-certain-patients. Published 2018.

  14. Hooton TM. Uncomplicated Urinary Tract Infection. N Engl J Med. 2012;366(11):1028–37. https://doi.org/10.1136/bmj.n725.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Krystal Hunter should be acknowledged for statistical support. The Female Pelvic Research Network through AUGS and SGS should be acknowledged for their support via project development and external site collaboration.

Funding

This study received no funding.

Author information

Authors and Affiliations

  1. Division of Female Pelvic Medicine & Reconstructive Surgery, Cooper University Healthcare, Philadelphia, PA, USA

    Tess Crouss & Lioudmila Lipetskaia

  2. Division of Female Pelvic Medicine & Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, USA

    Youngwu Kim

  3. Division of Female Pelvic Medicine & Reconstructive Surgery, Northwell Health, New Hyde Park, NY, USA

    Erica Lai & Vini Chopra

  4. Division of Female Pelvic Medicine & Reconstructive Surgery, Christiana Care, Newark, DE, USA

    Matthew Fagan

  5. Cooper Medical School of Rowan University, Camden, NJ, USA

    Lioudmila Lipetskaia

Authors
  1. Tess Crouss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Youngwu Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erica Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vini Chopra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthew Fagan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lioudmila Lipetskaia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

T Crouss: Project development, Data Collection, Manuscript writing; Y Kim: Data collection, manuscript editing; E Lai: Data collection, manuscript editing; V Chopra: Data collection, manuscript editing; M Fagan: Project development, manuscript editing; L Lipetskaia: Project development, manuscript editing

Corresponding author

Correspondence to Tess Crouss.

Ethics declarations

Conflicts of interest

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is part of the Fellows’ Pelvic Research Network.

This work was presented orally at the American Urogynecologic Society PDF Week, October 14, 2021.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crouss, T., Kim, Y., Lai, E. et al. Urinary tract infection following intradetrusor onabotulinumtoxina injection for non-neurogenic urgency incontinence: single- vs. multi-dose prophylactic antibiotic treatment regimens. Int Urogynecol J 34, 729–736 (2023). https://doi.org/10.1007/s00192-022-05236-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-022-05236-z

Keywords

Search

Navigation